Communiqués Amniotics AB

Actions

AMNI

SE0015961016

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,0055 ^SEK	-8,33%		+10,00%	-38,89%

20/05	Magle Chemoswed Holding AB (publ) (OM:MAGLE) a annulé l'acquisition de 99,96% des parts d'Amniotics AB (publ) (OM:AMNI) auprès de LSCS Invest AB, Deflexum AB, Marcus Larsson et autres.	CI
22/02	Amniotics AB (publ) annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Statement from the Board of Directors of Amniotics regarding the merger with Magle Group	30/05	AQ
Magle Group and Amniotics merge to create a leader in high-quality life-changing healthcare innovations with a broadened CDMO offering	30/05	AQ
Amniotics secures continued short-term capital needs by extending loan agreement and continued services under service agreement	21/05	AQ
Magle Group will not complete the public offer to the shareholders of Amniotics	20/05	AQ
MAGLE GROUP REPORTS OUTCOME AND EXTENDS THE ACCEPTANCE PERIOD FOR THE PUBLIC TENDER OFFER TO THE SHAREHOLDERS OF AMNIOTICS	07/05	AQ
Magle Chemoswed Q1 - Expansion by acquisition	19/04	AQ
Magle Chemoswed Holding AB publishes offer document and announces updated timetable regarding the cash offer to the shareholders of Amniotics AB	05/04	AQ
Magle Chemoswed Holding AB (publ) withdraws dividend proposal and enters into term loan facilities amounting to SEK 12 million in total	22/03	AQ
Statement from the Board of Directors of Amniotics regarding the public offer from Magle Chemoswed	22/03	AQ
Magle Chemoswed Holding AB announces a recommended cash offer of SEK 0.004 per share to the shareholders of Amniotics AB	22/03	AQ
Amniotics secures short-term capital needs by extending loan agreement and entering into a service agreement	21/03	AQ
Amniotics announces the outcome of the exercise of warrants series TO 3	11/03	AQ
The exercise period for warrants series TO 3 in Amniotics begins today	26/02	AQ
Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding	26/02	AQ
Amniotics AB (publ) Report for the fourth quarter 2023.	22/02	AQ
Information about the Annual General Meeting and appointed Nomination Committee of Amniotics	21/12	AQ
Amniotics receives orphan designation for PulmoStem® from the European Commission for the Treatment of Primary Graft Dysfunction following Lung Transplantation	14/12	AQ
Amniotics Q3 2023 - Rights Issue Foundation for Lung Transplantation Study	28/11	AQ
Amniotics AB (publ) Report for the third Quarter 2023	27/11	AQ
Renewed GMP certification	23/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Amniotics AB

Actions

AMNI

SE0015961016

Communiqués

Filtres